EyePoint Pharmaceuticals IncNASDAQ:EYPT
- LAST PRICE8.7900
- TODAY'S CHANGE (%)0.4400 (5.2695%)
- Bid / Lots8.7300/ 2
- Ask / Lots8.7900/ 7
- Open / Previous Close8.4000 / 8.3500
- Day Range
- 52 Week Range
- Volume185,661
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | EYPT |
|---|---|---|
| 09:32 ET | 9927 | 8.43 |
| 09:33 ET | 7282 | 8.45 |
| 09:35 ET | 1610 | 8.385 |
| 09:37 ET | 2248 | 8.36 |
| 09:39 ET | 6455 | 8.245 |
| 09:42 ET | 3513 | 8.22 |
| 09:44 ET | 8150 | 8.2 |
| 09:46 ET | 1399 | 8.3 |
| 09:48 ET | 2610 | 8.37 |
| 09:50 ET | 917 | 8.455 |
| 09:51 ET | 857 | 8.4353 |
| 09:53 ET | 5428 | 8.46 |
| 09:55 ET | 5252 | 8.505 |
| 09:57 ET | 1300 | 8.47 |
| 10:00 ET | 300 | 8.49 |
| 10:02 ET | 200 | 8.49 |
| 10:04 ET | 1848 | 8.45 |
| 10:06 ET | 800 | 8.445 |
| 10:08 ET | 892 | 8.51 |
| 10:09 ET | 300 | 8.48 |
| 10:11 ET | 2455 | 8.56 |
| 10:13 ET | 10930 | 8.59 |
| 10:15 ET | 1200 | 8.59 |
| 10:18 ET | 5527 | 8.585 |
| 10:20 ET | 5659 | 8.68 |
| 10:22 ET | 2750 | 8.6625 |
| 10:24 ET | 1862 | 8.675 |
| 10:26 ET | 4449 | 8.68 |
| 10:27 ET | 1944 | 8.64 |
| 10:29 ET | 41903 | 8.7 |
| 10:31 ET | 6187 | 8.74 |
| 10:33 ET | 5562 | 8.79 |
Nov 18, 2024
Press Release: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4), from 7:00AM ET on Monday Nov 18, 2024 by Dow Jones
7:00AM ET on Monday Nov 18, 2024 by Dow JonesEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4), from 7:00AM ET on Monday Nov 18, 2024 by Dow Jones
7:00AM ET on Monday Nov 18, 2024 by Dow Jones
Nov 11, 2024
DJ EyePoint Pharmaceuticals Is Maintained at Outperform by Baird, from 8:15AM ET on Monday Nov 11, 2024 by Dow Jones
8:15AM ET on Monday Nov 11, 2024 by Dow JonesDJ EyePoint Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co., from 7:24AM ET on Monday Nov 11, 2024 by Dow Jones
7:24AM ET on Monday Nov 11, 2024 by Dow Jones
Nov 8, 2024
DJ EyePoint Pharmaceuticals Is Maintained at Buy by Chardan Capital, from 5:24PM ET on Friday Nov 08, 2024 by Dow Jones
5:24PM ET on Friday Nov 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
EyePoint Pharmaceuticals Inc | 568.6M | -4.4x | --- |
Theravance Biopharma Inc | 470.1M | -9.4x | --- |
Aquestive Therapeutics Inc | 411.2M | -10.1x | --- |
ASP Isotopes Inc | 548.7M | -12.5x | --- |
Phathom Pharmaceuticals Inc | 646.2M | -1.7x | --- |
Daiichi Sankyo Co Ltd | 56.2B | 34.0x | --- |
Company Information
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Company’s other products include YUTIQ, and DEXYCU.
Contact Information
- Headquarters
- 480 Pleasant St Ste B300WATERTOWN, MA, United States 02472-2468
- Phone
- 617-926-5000
- Fax
- 617-926-5050
Executives
- Non-Executive Independent Chairman of the Board
- Goeran Ando
- President, Chief Executive Officer, Director
- Jay Duker
- Executive Vice Chairman of the Board
- Nancy Lurker
- Chief Financial Officer, Executive Vice President
- George Elston
- Chief Medical Officer
- Ramiro Ribeiro
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $568.6M |
|---|---|
Revenue (TTM) | $45.7M |
Shares Outstanding | 68.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.50 |
EPS | $-2.01 |
Book Value | $5.43 |
P/E Ratio | -4.4x |
Price/Sales (TTM) | 12.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -255.88% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
